US OptionsDetailed Quotes
PFE241220P26500
- 1.15
- +0.11+10.58%
15min DelayClose Dec 16 16:00 ET
1.15High1.01Low
1.10Open1.04Pre Close53 Volume2.49K Open Interest26.50Strike Price5.68KTurnover57.79%IV-0.40%PremiumDec 20, 2024Expiry Date1.25Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7986Delta0.2015Gamma18.10Leverage Ratio-0.0568Theta-0.0017Rho-14.45Eff Leverage0.0068Vega
Pfizer Stock Discussion
Sign in to post a comment
$Pfizer (PFE.US)$ People like you and me can make money in so many other stocks. But if you invest in Pfizer you invest in your own death. This is just my personnel opinion. I know keep emotions out of market but not in this case for me. I don’t care stock price of such companies whether it goes up or down. I will not put penny in such companies. They sell death. Never invest in Vaccine companies again. Boycott everyone of them.
2
3
$Pfizer (PFE.US)$
Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1) . The accompanying presentation can be found at .
Full-Year 2025 Revenue Guidance(1)
Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring reve...
Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1) . The accompanying presentation can be found at .
Full-Year 2025 Revenue Guidance(1)
Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring reve...
1
1
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
10
1
4
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
A quick update of my trading activities in this week (9 to 13 Dec 2024).
New Positions
$Symbotic (SYM.US)$ , $IonQ Inc (IONQ.US)$ , $Alphabet-A (GOOGL.US)$ , $PepsiCo (PEP.US)$ , $Futu Holdings Ltd (FUTU.US)$
Sold out Positions
$Hershey (HSY.US)$ , $UnitedHealth (UNH.US)$ , $Taiwan Semiconductor (TSM.US)$
Increased / Decreased Positions
None
Remarks
- I sold out $Hershey (HSY.US)$ after buyout news came out. I took decent profit from this rumour.
- Just few days after I bought $UnitedHealth (UNH.US)$ , I sold ...
New Positions
$Symbotic (SYM.US)$ , $IonQ Inc (IONQ.US)$ , $Alphabet-A (GOOGL.US)$ , $PepsiCo (PEP.US)$ , $Futu Holdings Ltd (FUTU.US)$
Sold out Positions
$Hershey (HSY.US)$ , $UnitedHealth (UNH.US)$ , $Taiwan Semiconductor (TSM.US)$
Increased / Decreased Positions
None
Remarks
- I sold out $Hershey (HSY.US)$ after buyout news came out. I took decent profit from this rumour.
- Just few days after I bought $UnitedHealth (UNH.US)$ , I sold ...
loading...
7
$Pfizer (PFE.US)$
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.
"Our decision to increase our quarterly dividend underscores our strong fi...
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.
"Our decision to increase our quarterly dividend underscores our strong fi...
6
7
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Slowly melting away my hope
The $Nasdaq Composite Index (.IXIC.US)$ hit a record intraday and closing high Wednesday, crossing 20,000 points for the first time. The index was up 1.8% at 20,050 in late trading, finishing 1.77% higher. The $S&P 500 Index (.SPX.US)$ closed just below its highest close on record at 6,090.27, while the $Dow Jones Industrial Average (.DJI.US)$ fell 0.2%.
MACRO
In economic news, November’s consumer price index (C...
MACRO
In economic news, November’s consumer price index (C...
38
4
10
News Highlights
On Friday evening, $Super Micro Computer (SMCI.US)$ revealed that Nasdaq had approved their appeal for additional time to submit crucial documents. Following this news, Super Micro's shares saw a significant increase after trading hours, furthering its impressive recovery since mid-November.
The most traded calls are contracts of $45 strike price that expire on Dec. 6. The total v...
On Friday evening, $Super Micro Computer (SMCI.US)$ revealed that Nasdaq had approved their appeal for additional time to submit crucial documents. Following this news, Super Micro's shares saw a significant increase after trading hours, furthering its impressive recovery since mid-November.
The most traded calls are contracts of $45 strike price that expire on Dec. 6. The total v...
+2
49
4
35
No comment yet
Netvista91 : I with YOU bro. I totally agreeeeeee. Boycott the until Ground
72358569 : This is a good, very good company with long history. If there are things wrong , ie vaccine, remember it’s the ppl or the management or even the government who should be responsible, not the company itself!
Trushar Rathod OP 72358569 : Sell this to someone else. Boycott vaccine companies period. Doesn’t matter if it’s good company or not. Say NO to vaccines and they will all disappear for good.